Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review

@article{Lete2015HaemostaticAM,
  title={Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review},
  author={I. Lete and N. Chabbert-Buffet and C. Jamin and S. Lello and P. Lobo and R. Nappi and A. Pintiaux},
  journal={The European Journal of Contraception \& Reproductive Health Care},
  year={2015},
  volume={20},
  pages={329 - 343}
}
Abstract Objective Since its introduction 50 years ago, the contraceptive pill has continuously evolved to decrease the risk of venous thromboembolism (VTE) associated with its use. An increased risk of VTE still remains, however. Other concerns, such as effects on lipid and carbohydrate metabolism, have also been reported. In this study we compared two reference combined oral contraceptives (COCs) containing ethinylestradiol (EE)/levonorgestrel (LNG) and EE/drospirenone (DRSP) with COCs… Expand
Metabolic impact of combined hormonal contraceptives containing estradiol
TLDR
The preliminar parenteral use of E2 seems promising, both transdermal and vaginal, in particular after the introduction of a specific progestin with a high anti-ovulatory activity, like nestorone. Expand
Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis
ABSTRACT Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations.Expand
The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism
TLDR
A narrative review of the available data on the pharmacotherapy of NGM in combined hormonal contraceptives (CHCs) in terms of contraceptive efficacy, venous thromboembolism risk, safety, tolerability and bleeding patterns is reviewed. Expand
Estradiol in non-oral hormonal contraception: a “long and winding road”
TLDR
A recent observational study of a cohort of more than 50,000 new COC users indicates, though with important limitations of real-world data, that the risk of venous thromboembolism (VTE) andother cardiovascular events is similar andpossibly lower with the use of E2 containing pills if compared with EE. Expand
Body composition and psychological improvement in healthy premenopausal women assuming the oral contraceptive containing micronized estradiol (E2) and nomegestrol acetate (NOMAC)
  • M. Neri, M. E. Malune, +7 authors A. Paoletti
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2017
TLDR
The study suggests that E2/NOMAC is devoid of negative effects on AI and BC, with additional benefits on PS and dysmenorrhea. Expand
Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle?
  • G. Grandi, F. Facchinetti, J. Bitzer
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2017
TLDR
The International Active Surveillance study ‘Safety of Contraceptives: role of Estrogens’ (INAS-SCORE) investigated the cardiovascular risks and the effectiveness associated with the use of the CHC containing E2V/DNG compared to other EE-based ones in a routine clinical setting. Expand
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
TLDR
Specific attention will be given to the endogenous thrombin potential-based activated protein C resistance, a test aiming at assessing the thrombogenicity induced by hormonal therapies and inherited or acquiredThrombophilia. Expand
Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)
  • A. Cagnacci, C. Bastianelli, +8 authors A. Volpe
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2018
TLDR
The real-world experience of women receiving NOMAC/E2 indicated very good treatment continuation, high satisfaction and significantly improved menstrual cycle-related symptoms. Expand
An update on new orally administered contraceptives for women
  • A. Nelson
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2015
TLDR
This article reviews the features of each of the four new oral contraceptives that have been introduced in the United States and/or Europe in the last few years and concludes that cost will continue to be the determining factor in the acceptance of these new products, unless substantial health benefits can be conclusively proven. Expand
Fifty-five years on: Where is the contraceptive pill?
TLDR
One of the adverse effects of combined hormonal contraceptives is an increased risk of developing venous thromboembolism in its two clinical presentations: deep vein thrombosis (DVT) and pulmonary embolism (PE). Expand
...
1
2
...

References

SHOWING 1-10 OF 87 REFERENCES
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
TLDR
The NOMAC/E2 pill regimen has fewer adverse effects on blood biological coagulation and fibrinolysis markers than LNG/EE, and could have a more favourable venous thromboembolism risk profile than Lng/EE. Expand
Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism
  • U. Ågren, Marjatta Anttilat, +4 authors E. Mommers
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2011
TLDR
The monophasic COC NOMAC/E2 had less influence on haemostasis, lipids and carbohydrate metabolism than the COC LNG/EE. Expand
Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive
TLDR
E2V/DNG had a minimal impact on metabolic and haemostatic parameters, and a more favourable effect than EE/LNG on lipid markers, and both formulations were well tolerated, with no serious adverse events reported. Expand
Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.
TLDR
A brief summary of the pharmacology of EE and E₂, including metabolism, pharmacokinetics and pharmacodynamics, as well as adverse effects of these estrogens are provided. Expand
Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive
TLDR
The novel COC containing estradiol valerate/dienogest had similar or less pronounced effects on hemostatic parameters than ethinylestradiol/ levonorgestrel. Expand
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism
TLDR
A very recent systematic review and meta-analysis of the possible link between treatment with CHCs and VTE concluded that those containing desogestrel, DRSP or CPA were associated with a significantly higher risk than CHCs containing LNG, and the augmented risk of VTE found for pills containing gestodene compared to COCs with LNG appeared to be smaller than in earlier studies. Expand
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
TLDR
The results of a cycle-controlled randomized cross-over study determined the effects of so-called second and third generation OC's on a number of anticoagulant parameters, which indicate that the activity of the anticoaggulant pathways in plasma from users of desogestrel-containing OC is more extensively impaired than in plasmaFrom users of levonorgestrel -containing OC. Expand
Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism.
TLDR
The lack of differences with regard to established risk markers of VTE gives further support to the findings of the most recent epidemiological studies, which have not found any difference in the risk of V TE between third- and second-generation OCs. Expand
Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.
TLDR
At almost equivalent estrogen doses, a phasic OC containing DSG compared with LNG has a less androgenic effect on lipoproteins and SHBG, similar effects on hemostatic parameters with lower protein S and factor V activity and equivalent effects on carbohydrate metabolism. Expand
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
TLDR
There are differences between the effects of levonorgestrel and desogestrel-containing OC's on some coagulation factors which, if affected simultaneously, may tip the hemostatic balance towards a prethrombotic state and may lead to overt clinical venous thromboembolism. Expand
...
1
2
3
4
5
...